FDA Summarizes Strategy to Keep Baby Formula SafeFDA Summarizes Strategy to Keep Baby Formula Safe
The U.S. Food and Drug Administration released a national strategy revealing actions the agency will take immediately to help ensure access to safe, nutritious infant formula and to increase resiliency of the US infant formula market and supply.
March 28, 2023
The Food and Drug Omnibus Reform Act of 2022 (FDORA) directed the FDA, in consultation with other federal government partners, to develop this immediate strategy to increase the resiliency of the U.S. infant formula market. Key elements of the immediate strategy released today include:
Ensuring industry is aware of requirements to develop and implement redundancy risk management plans. These plans are intended to help industry identify risks to the supply chains of infant formula and medical foods and to develop mitigation plans against potential disruptions that could impact production.
Continuing to enhance inspections of infant formula manufacturers, including by expanding and improving infant formula training for investigators.
Expediting review of premarket submissions for new infant formula products to mitigate or prevent shortages.
Continuing to monitor the infant formula supply and developing a forecasting model to enable FDA to prepare for and mitigate future supply disruptions.
Engaging with US government partners who play a role in mitigating other factors that may influence the infant formula supply, such as tariffs and market concentration, to sustain the safe, continuous production of infant formula.
Engaging with the US Department of Agriculture to support efforts to build resiliency within its Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
Continuing to advance the agency’s Strategy to Help Prevent Cronobacter sakazakii Illnesses Associated with Consumption of Powdered Infant Formula.
Improving the agency’s consumer education materials relating to infant formula on FDA.gov.
Enhancing and leveraging the FDA’s partnerships with health care providers and professionals, particularly infant care professionals, to further expand the agency’s consumer education program.
These actions are underway.
FDORA also asked the FDA to trace the events that led up to and followed the voluntary recall of infant formula in February 2022 by Abbott Nutrition, the temporary pause in production at the facility in Sturgis, MI, and the numerous factors that contributed to the fragility of this particular supply chain.
“The events that led up to and ultimately resulted in the voluntary recall of certain infant formula products in February 2022 shocked the infant formula supply in the U.S., creating an unparalleled challenge for parents and caregivers,” said Susan Mayne, director of the FDA’s Center for Food Safety and Applied Nutrition. “Since then, the agency has had ongoing and extensive engagement with the infant formula industry to identify and implement opportunities to strengthen preventive control practices. The immediate strategy released today will play an important role in increasing the resiliency of the infant formula market as the agency continues its critical work to improve industry’s processes and programs for the protection of those who rely on infant formula while incentivizing additional infant formula manufacturers to enter the market.”
The strategy also describes initial actions the FDA took to address the infant formula shortage and details the agency’s plans for improving the safety and resiliency of the infant formula supply, while noting considerations beyond the purview of the FDA.
The agency remains committed to improving the infant formula supply and ensuring that consumers have the utmost confidence that infant formula available in the U.S. is safe and nutritious.
Along with input from the National Academies of Science, Engineering and Medicine (NASEM), this initial strategy is a first step toward issuing a long-term national strategy, also called for in FDORA, to improve preparedness against infant formula shortages by outlining methods to improve information-sharing, recommending measures for protecting the integrity of the infant formula supply chain and preventing contamination.
Thelong-term strategy will follow this plan and outline methods to incentivize entry of new infant formula manufacturers to increase supply and mitigate future shortages and recommend necessary authorities to gain insight into the supply chain and risks for shortages.
The long-term strategy is due to Congress one year after enactment, or 90 days after the NASEM issues its report. The FDA anticipates issuing this strategy publicly in early 2024.
About the Author(s)
You May Also Like
USDA Recall Report: November 2023Dec 05, 2023
8 Chemical Plant Workers Treated for Toxic Chemical ExposureDec 05, 2023
Fire Erupts at ADM Soy Processing PlantDec 05, 2023
CSB Releases Final Report in Fatal Vapor ExplosionDec 05, 2023